{
    "nct_id": "NCT05558124",
    "official_title": "A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia",
    "inclusion_criteria": "* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged ≥18 and ≤70 years with newly diagnosed any risk AML as defined by ELN 2017 criteria\n* For females of child-bearing potential: use of highly effective contraception upon enrollment and during study participation and for an additional 6 months after the end of CPX-351 and Gemtuzumab ozogamicin administration: A female of child-bearing potential is considered when a sexually mature female: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months\n* The effects of CPX-351 and gemtuzumab ozogamicin on the developing human fetus are unknown. For this reason, women of child-bearing potential as defined above must have a negative serum or urine pregnancy test within 24 hours prior to beginning study treatment.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner\n* Myeloblasts expressing CD33 as determined by flow cytometry or immunohistochemistry\n* ECOG ≤ 2 and eligible to receive intensive chemotherapy as determined by the treating physician\n* Prior malignancy is allowed providing it does not require concurrent therapy. Exception: Active hormonal therapy is allowed.\n* Prior hypomethylating agents (HMA) therapy including azacitidine or decitabine when used for non-AML diagnoses is allowed. Most recent dose must have been ≥14 days prior to day 1 of study treatment.\n* Participants must have acceptable organ function\n* Adequate cardiac function defined as ejection fraction of ≥50% as determined by multigated acquisition scan (MUGA) or 2D echocardiogram.\n* Hydroxyurea is allowed for cytoreduction until day 1 of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Prior treatment of AML except hydroxyurea and/or leukapheresis\n* Participants with acute promyelocytic leukemia (APL).\n* Known current and clinically active central nervous system (CNS) leukemia.\n* Severe liver disease (cirrhosis, non-alcoholic steatohepatitis, sclerosing cholangitis) or patients with known Wilson's disease.\n* Participants with known active infection with hepatitis B or hepatitis C virus\n* Known allergic reactions to components of the CPX-351 (cytarabine or daunorubicin) or Gemtuzumab ozogamicin.\n* Patients with any prior anthracycline exposure plus any planned on-study anthracycline exposure cannot not exceed 550 mg/m2 of daunorubicin (or equivalent). For participants who have received radiation therapy to the mediastinum, the total cumulative dose of anthracycline should not exceed 400 mg/m2 of daunorubicin(or equivalent).\n* Hemodynamically unstable (subjects requiring vasopressor support will not be eligible).\n* Treatment with another investigational drug within 14 days.\n* Uncontrolled cardiac disease including congestive heart failure class III or IV by the NYHA, unstable angina (angina symptoms at rest), new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.\n* Any disorder that compromises the subject's ability to give written informed consent and/or to comply with study procedures.\n* Any substance abuse, severe and/or uncontrolled medical, social or psychiatric conditions that may prevent the subject from completing the study, interfere with the evaluation of safety and/or efficacy, or interfere with the interpretation of the study results.\n* Female subject who is pregnant or breastfeeding.\n* Any patient with a known FLT3 ITD or FLT3 TKD mutation",
    "miscellaneous_criteria": ""
}